What is the current Nucleic acid-based Therapeutics Drug market size?

The current market size is approximately USD 1.2 billion as of 2023, with a future outlook of significant growth.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Nucleic acid-based Therapeutics Drug market?

Key drivers include advancements in technology and rising prevalence of genetic disorders, fueling market expansion.

What challenges does the Nucleic acid-based Therapeutics Drug market face?

Challenges include high development costs, regulatory hurdles, and competition from established therapies, impacting growth.

Which regions are leading the Nucleic acid-based Therapeutics Drug market?

North America and Europe are currently leading the market, with Asia-Pacific emerging as a key growth region.

Who are the top companies in the Nucleic acid-based Therapeutics Drug market?

Top companies include Biogen, Gilead Sciences, and Pfizer, driving innovation and investment in the market.

What future opportunities exist in the Nucleic acid-based Therapeutics Drug market?

Future opportunities include emerging applications in rare diseases, cancer, and infectious diseases, offering significant potential.

How is technology impacting the Nucleic acid-based Therapeutics Drug market?

Advances in gene editing, RNA interference, and nanotechnology are transforming the market, enabling innovative therapies.

What is the current regulatory landscape for the Nucleic acid-based Therapeutics Drug market?

The regulatory landscape is evolving, with agencies like the FDA and EMA providing guidance on development, approval, and commercialization.

How will the Nucleic acid-based Therapeutics Drug market size change in the next 5 years?

The market size is expected to increase significantly, driven by growing demand, advancements in technology, and expanding applications.

Nucleic acid-based Therapeutics Drug Size, Share & Forecast Analysis 2025–2033

Nucleic acid-based Therapeutics Drug by Application (Neuromuscular Diseases, hATTR, COVID-19, Other), by Types (Antisense Oligonucleotides (ASO), siRNA, mRNA), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 153

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 153

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Nucleic acid-based Therapeutics Drug Market Overview

The Nucleic acid-based Therapeutics Drug market refers to the industry focused on developing and commercializing therapies based on nucleic acids, such as DNA and RNA, to treat various diseases. As the Nucleic acid-based Therapeutics Drug market size is expected to reach $13.9 billion by 2026, the growth outlook and market forecast indicate a significant expansion of the industry, driven by advancements in gene therapy and RNA-based therapeutics. The market's industry expansion is anticipated to be fueled by increasing investments in research and development, leading to the emergence of new products and technologies, including mRNA-based vaccines and gene editing tools.

Loading chart…

The Nucleic acid-based Therapeutics Drug market is expected to grow at a CAGR of 15.6% during the forecast period, driven by key forces such as technological advancements in gene editing and RNA-based therapeutics, regulatory support for innovative therapies, and increasing demand for personalized medicine. The largest region in the market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing investments in biotechnology research and clinical trials. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments shaping the Nucleic acid-based Therapeutics Drug industry.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sarepta Therapeutics; Ionis Pharmaceuticals; Alnylam; Biogen; Nippon Shinyaku; Sobi; Novartis; BioNTech; Pfizer; Moderna Therapeutics; Jazz Pharmaceuticals; CureVac; Regulus Therapeutics; ProQR; Secarna; MiNA Therapeutics; Sylentis; Arrowhead; Silence Therapeutics; Dicerna
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Nucleic acid-based Therapeutics Drug market is poised for significant growth, driven by factors such as advancements in genetic engineering and the increasing prevalence of genetic disorders. As the market continues to evolve, understanding the key dynamics driving growth, restraints, opportunities, and challenges is crucial for stakeholders to make informed decisions.

Growth Drivers2 items

The rising demand for personalized medicine and targeted therapies is expected to drive the Nucleic acid-based Therapeutics Drug market size, with a growth forecast indicating a significant increase in the adoption of these therapies.

Advances in technologies such as CRISPR gene editing and RNA interference are expanding the potential applications of nucleic acid-based therapeutics, further fueling market growth.

Restraints2 items

High development costs and regulatory hurdles are significant restraints in the Nucleic acid-based Therapeutics Drug market, potentially limiting the entry of new players and slowing the pace of innovation.

Concerns over the safety and efficacy of nucleic acid-based therapeutics, including the risk of off-target effects, may also hinder market growth if not adequately addressed through rigorous testing and validation.

Opportunities2 items

The increasing focus on precision medicine and the potential for nucleic acid-based therapeutics to address previously untreatable conditions presents a significant opportunity for market expansion and innovation.

Partnerships and collaborations between biotechnology firms, research institutions, and pharmaceutical companies can facilitate the development and commercialization of new nucleic acid-based therapies, driving growth in the Nucleic acid-based Therapeutics Drug market.

Challenges2 items

Ensuring the scalability and cost-effectiveness of nucleic acid-based therapeutic production is a critical challenge that must be overcome to achieve widespread adoption and realize the full growth forecast of the Nucleic acid-based Therapeutics Drug market.

Addressing ethical considerations and regulatory frameworks related to the use of genetic information and editing technologies will be essential for the long-term sustainability and growth of the Nucleic acid-based Therapeutics Drug market size.

Market Segmentation

Loading chart…

The Nucleic acid-based Therapeutics Drug market can be segmented based on Application, which includes subtypes such as cancer treatment, infectious diseases, and genetic disorders. This segmentation contributes to the overall market size by highlighting the specific areas where nucleic acid-based therapeutics are most effective, thus guiding investment and research decisions. The Nucleic acid-based Therapeutics Drug segmentation by application helps in understanding the demand for these therapeutics in different disease areas.

Another crucial segmentation of the Nucleic acid-based Therapeutics Drug market is by Types, which encompasses subtypes like RNA-based therapeutics and DNA-based therapeutics. This categorization is vital as it defines how the therapeutics are designed and delivered, influencing their efficacy and safety profiles. By analyzing the market taxonomy of nucleic acid-based therapeutics by type, stakeholders can better comprehend the technological advancements and the potential for innovation in this field, ultimately contributing to the growth of the Nucleic acid-based Therapeutics Drug market.

Nucleic acid-based Therapeutics Drug Segmentation Breakdown9 items

Application

Neuromuscular Diseases

hATTR

COVID-19

Other

Types

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Regional Insights

Loading chart…

The Nucleic acid-based Therapeutics Drug market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of nucleic acid-based therapeutics, favorable policies, and significant investments in the region's healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and significant investments in research and development. In Europe, drivers include favorable policies, a strong infrastructure, and a high level of adoption of nucleic acid-based therapeutics. Asia Pacific is driven by increasing adoption, rising demographics, and significant investments in the region's healthcare sector. Latin America and Middle East & Africa are expected to be driven by improving infrastructure, increasing adoption, and growing ecosystem maturity.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by the increasing demand for nucleic acid-based therapeutics and the region's growing ecosystem maturity. The Nucleic acid-based Therapeutics Drug market growth in Latin America and Middle East & Africa is expected to be driven by improving infrastructure and increasing adoption of nucleic acid-based therapeutics.

Competitive Landscape

The Nucleic acid-based Therapeutics Drug market is moderately consolidated, driven by a mix of global players and local/regional companies. The Nucleic acid-based Therapeutics Drug competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on product innovation and regulatory approvals to maintain their competitive edge, while local/regional companies are emphasizing distribution and pricing strategies to gain market share.

Companies in this market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Common differentiation strategies include technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on innovation, quality, and customer service.

Sarepta Therapeutics: regional expansion

Ionis Pharmaceuticals: innovation pipeline

Alnylam: premium pricing

Biogen: vertical integration

Nippon Shinyaku: local manufacturing

Sobi: OEM tie-ups

Key Nucleic acid-based Therapeutics Drug Companies20 items

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market Ecosystem

The Nucleic acid-based Therapeutics Drug ecosystem spans upstream, midstream, and downstream activities, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of nucleic acid-based therapeutics, with each participant contributing to the overall workflow. The ecosystem's boundaries are defined by the interactions between these stakeholders, from raw material suppliers to end users, with each segment influencing the flow of value.

Raw material suppliers — providing nucleic acid components

Technology providers — developing nucleic acid-based therapeutics

OEMs / manufacturers — producing final therapeutics products

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — overseeing safety and efficacy standards

In the Nucleic acid-based Therapeutics Drug ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through safety and efficacy approvals. Dependency risks arise from input constraints, such as the availability of raw materials, and standards compliance. Switching costs and partnerships are critical, as companies may need to adapt to changing regulatory requirements or form alliances to ensure interoperability. As the ecosystem differs by region, with varying regulatory frameworks and market conditions, companies must navigate these complexities to succeed in the global Nucleic acid-based Therapeutics Drug ecosystem.

Recent Industry Insights

The Nucleic acid-based Therapeutics Drug industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between major pharmaceutical companies and biotech firms have accelerated the development of nucleic acid-based therapies. Notable examples include collaborations focused on RNA interference and gene editing technologies. Additionally, there have been several mergers & acquisitions and product launches, further expanding the industry's landscape.

Regulatory changes, such as the FDA's updated guidelines for gene therapy products, have also impacted the industry. Furthermore, a shift in consumer trends towards personalized medicine has driven demand for nucleic acid-based therapeutics. The industry has seen significant funding rounds and expansions, with several companies securing investments to advance their research and development efforts.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Nucleic acid-based Therapeutics Drug market. The market attractiveness is high due to the increasing demand for innovative treatments. The competitive intensity is moderate, with key players investing in research and development. The long-term outlook for the Nucleic acid-based Therapeutics Drug market outlook is promising, driven by advancements in technology and rising investments. The innovation landscape is dynamic, with ongoing discoveries in the field of nucleic acid-based therapeutics.

The demand-supply balance is favorable, with growing demand for these therapeutics. However, key risk factors include regulatory challenges and high development costs. Overall, the market offers opportunities for growth and innovation, making it an attractive space for investors and pharmaceutical companies.

11 items

1. Executive Summary

2. Nucleic acid-based Therapeutics Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Nucleic acid-based Therapeutics Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Nucleic acid-based Therapeutics Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Neuromuscular Diseases

6.1.2. hATTR

6.1.3. COVID-19

6.1.4. Other

6.2. Global Nucleic acid-based Therapeutics Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antisense Oligonucleotides (ASO)

6.2.2. siRNA

6.2.3. mRNA

6.3. Global Nucleic acid-based Therapeutics Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Nucleic acid-based Therapeutics Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Nucleic acid-based Therapeutics Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Nucleic acid-based Therapeutics Drug Market Competition by Key Manufacturers

8.1. Global Nucleic acid-based Therapeutics Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Nucleic acid-based Therapeutics Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sarepta Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Ionis Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Alnylam

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biogen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Nippon Shinyaku

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sobi

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BioNTech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Moderna Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Jazz Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CureVac

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Regulus Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. ProQR

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Secarna

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. MiNA Therapeutics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sylentis

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Arrowhead

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Silence Therapeutics

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Dicerna

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Nucleic acid-based Therapeutics Drug Market

Figure 4: Global Nucleic acid-based Therapeutics Drug Market: Drivers

Figure 5: Global Nucleic acid-based Therapeutics Drug Market: Challenges

Figure 6: Global Nucleic acid-based Therapeutics Drug Market: Trends

Figure 7: Global Nucleic acid-based Therapeutics Drug Market: Opportunity

Figure 8: Global Nucleic acid-based Therapeutics Drug Market: Restraint

Figure 9: Global Nucleic acid-based Therapeutics Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Nucleic acid-based Therapeutics Drug Market Value (USD Million) By Region

Figure 15: Global Nucleic acid-based Therapeutics Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Nucleic acid-based Therapeutics Drug Market Value (USD Million) By Region

Figure 23: Global Nucleic acid-based Therapeutics Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Nucleic acid-based Therapeutics Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Nucleic acid-based Therapeutics Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Nucleic acid-based Therapeutics Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Nucleic acid-based Therapeutics Drug Market Value (USD Million) By Region

Table 10: Global Nucleic acid-based Therapeutics Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Nucleic acid-based Therapeutics Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Nucleic acid-based Therapeutics Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Nucleic acid-based Therapeutics Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sarepta Therapeutics Basic Information And Sales Area

Table 31: Sarepta Therapeutics. Products Portfolio

Table 32: Ionis Pharmaceuticals Basic Information And Sales Area

Table 33: Ionis Pharmaceuticals. Products Portfolio

Table 34: Alnylam Basic Information And Sales Area

Table 35: Alnylam. Products Portfolio

Table 36: Biogen Basic Information And Sales Area

Table 37: Biogen. Products Portfolio

Table 38: Nippon Shinyaku Basic Information And Sales Area

Table 39: Nippon Shinyaku. Products Portfolio

Table 40: Sobi Basic Information And Sales Area

Table 41: Sobi. Products Portfolio

Table 42: Novartis Basic Information And Sales Area

Table 43: Novartis. Products Portfolio

Table 44: BioNTech Basic Information And Sales Area

Table 45: BioNTech. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Moderna Therapeutics Basic Information And Sales Area

Table 49: Moderna Therapeutics. Products Portfolio

Table 50: Jazz Pharmaceuticals Basic Information And Sales Area

Table 51: Jazz Pharmaceuticals. Products Portfolio

Table 52: CureVac Basic Information And Sales Area

Table 53: CureVac. Products Portfolio

Table 54: Regulus Therapeutics Basic Information And Sales Area

Table 55: Regulus Therapeutics. Products Portfolio

Table 56: ProQR Basic Information And Sales Area

Table 57: ProQR. Products Portfolio

Table 58: Secarna Basic Information And Sales Area

Table 59: Secarna. Products Portfolio

Table 60: MiNA Therapeutics Basic Information And Sales Area

Table 61: MiNA Therapeutics. Products Portfolio

Table 62: Sylentis Basic Information And Sales Area

Table 63: Sylentis. Products Portfolio

Table 64: Arrowhead Basic Information And Sales Area

Table 65: Arrowhead. Products Portfolio

Table 66: Silence Therapeutics Basic Information And Sales Area

Table 67: Silence Therapeutics. Products Portfolio

Table 68: Dicerna Basic Information And Sales Area

Table 69: Dicerna. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Nucleic acid-based Therapeutics Drug Market Value (USD Million) By Region

Table 75: Global Nucleic acid-based Therapeutics Drug Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Nucleic acid-based Therapeutics Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sarepta Therapeutics; Ionis Pharmaceuticals; Alnylam; Biogen; Nippon Shinyaku; Sobi; Novartis; BioNTech; Pfizer; Moderna Therapeutics; Jazz Pharmaceuticals; CureVac; Regulus Therapeutics; ProQR; Secarna; MiNA Therapeutics; Sylentis; Arrowhead; Silence Therapeutics; Dicerna
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in technologies such as CRISPR gene editing and RNA interference are expanding the potential applications of nucleic acid-based therapeutics, further fueling market growth.

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Nucleic acid-based Therapeutics Drug Segmentation Breakdown9 items

Application

Neuromuscular Diseases

hATTR

COVID-19

Other

Types

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Regional Insights

Loading chart…

Competitive Landscape

Sarepta Therapeutics: regional expansion

Ionis Pharmaceuticals: innovation pipeline

Alnylam: premium pricing

Biogen: vertical integration

Nippon Shinyaku: local manufacturing

Sobi: OEM tie-ups

Key Nucleic acid-based Therapeutics Drug Companies20 items

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market Ecosystem

Raw material suppliers — providing nucleic acid components

Technology providers — developing nucleic acid-based therapeutics

OEMs / manufacturers — producing final therapeutics products

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — overseeing safety and efficacy standards

Recent Industry Insights

Analyst Overview

Table of Contents